共 34 条
Discovery and characterization of selective small molecule inhibitors of the mammalian mitochondrial division dynamin, DRP1
被引:23
|作者:
Mallat, A.
[1
]
Uchiyama, L. F.
[2
]
Lewis, S. C.
[2
]
Fredenburg, R. A.
[1
]
Terada, Y.
[3
]
Ji, N.
[1
]
Nunnari, J.
[2
]
Tseng, C. C.
[1
]
机构:
[1] Mitobridge Inc, Cambridge, MA 02138 USA
[2] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA
[3] Astellas Pharma Inc, Drug Discovery Res, Tsukuba, Ibaraki, Japan
关键词:
DRP1;
Mitochondria;
Small molecule inhibitor;
Fission;
Dynamics;
FISSION;
FUSION;
NEURODEGENERATION;
PROTEIN-1;
PROTECTS;
D O I:
10.1016/j.bbrc.2018.03.189
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Balanced rates of mitochondrial division and fusion are required to maintain mitochondrial function, as well as cellular and organismal homeostasis. In mammals, the cellular machines that mediate these processes are dynamin-related GTPases; the cytosolic DRP1 mediates division, while the outer membrane MFN1/2 and inner membrane OPA1 mediate fusion. Unbalanced mitochondrial dynamics are linked to varied pathologies, including cell death and neurodegeneration, raising the possibility that small molecules that target the division and fusion machines to restore balance may have therapeutic potential. Here we describe the discovery of novel small molecules that directly and selectively inhibit assembly-stimulated GTPase activity of the division dynamin, DRP1. In addition, these small molecules restore wild type mtDNA copy number in MFN1 knockout mouse embryonic fibroblast cells, a phenotype linked to deficient mitochondrial fusion activity. Thus, these compounds are unique tools to explore the roles of mitochondrial division in cells, and to assess the potential therapeutic efficacy of rebalancing mitochondrial dynamics in pathologies associated with excessive mitochondrial division. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:556 / 562
页数:7
相关论文